Journal of International Psychiatry

[Abstract] Objective: To explore the total efficacy and safety of fluvoxamine in the treatment of children and adolescents with obsessive-compulsive disorder. Methods: 90 children and adolescents with obsessive-compulsive disorder from March 2020 to July 2021 were selected. Referring to the "random number table method", the subjects were divided into two groups: control group and observation group (all n = 45 cases). The control group was treated with clomipramine and the observation group was treated with fluvoxamine. Evaluation indexes: total clinical efficacy, obsessive-compulsive symptom score [Yale Brown Obsessive-Compulsive Scale (Y-BOCS)], anxiety score [Hamilton Anxiety Scale (HAMA)], adverse reaction rate [Treatment Emergent Symptom Scale (TESS)], quality of life score [brief form of health survey] （the MOS item short from health survey. Results: The total curative effect of the observation group was significantly higher than that of the control group (P<0.05); at the same time, the Y-BOCS score and HAMA score of the observation group were significantly lower than those of the control group 4 weeks and 8 weeks before treatment (P<0.05); the incidence of adverse reactions between the two groups (P>0.05); the SF-36 (role, society, body and cognition) score of the observation group was higher than that of the control group (P<0.05). Conclusion: fluvoxamine combined with clomipramine is more effective than single drug in children and adolescents with obsessive-compulsive disorder, and the drug safety is guaranteed.

[Key words] children and adolescents with obsessive-compulsive disorder; fluvoxamine; clinical efficacy